RxDoctor Payments Data

Lesle Long, MD

Internal Medicine · Greer, SCNPI 1528045069

Payments from drug & device makers

$1,878in general payments, 2019–2025

Across 95 payments — averaging $19.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$215
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$184
  • Phathom Pharmaceuticals, Inc.$170
  • Braeburn Inc.$168
  • Novo Nordisk$165
  • Pfizer$115
  • plus $860 from 20 others

What the payments were for

  • Food & beverage$1,878100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,878 in reported general payments places this provider in the 75th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$76,314
Medicare patients
215
Services billed
742

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide106$118,942
EliquisApixaban38$37,275
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl240$28,966
MyrbetriqMirabegron28$26,047
SuboxoneBuprenorphine Hcl/Naloxone Hcl65$19,102
XareltoRivaroxaban19$16,135
Buprenorphine Hcl204$9,590
Testosterone26$6,327
ZubsolvBuprenorphine Hcl/Naloxone Hcl11$4,803
SynthroidLevothyroxine Sodium68$3,443
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$3,024
Duloxetine Hcl65$2,935
Levothyroxine Sodium240$2,656
Fluticasone-SalmeterolFluticasone Propion/Salmeterol24$2,346
Rosuvastatin Calcium224$2,284

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$165$118,942106 claims
PfizerEliquis$115$37,27538 claims
Indivior Inc.Suboxone$108$19,10265 claims
AbbVieSynthroid$215$3,44368 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Greer

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →